

Unchalee Permsuwan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5702384/publications.pdf>

Version: 2024-02-01

35
papers

515
citations

759233
12
h-index

713466
21
g-index

35
all docs

35
docs citations

35
times ranked

719
citing authors

#	ARTICLE	IF	CITATIONS
1	The affordability of adding a direct-acting oral anticoagulant to the national list of essential medicine for patients with non-valvular atrial fibrillation in Thailand: a budget impact analysis. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 93-100.	1.4	2
2	Cost-Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand. Advances in Therapy, 2022, 39, 1279-1292.	2.9	10
3	Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand. Applied Health Economics and Health Policy, 2022, 20, 587-596.	2.1	2
4	Economic Burdens for Treatment of Patients With Type 2 Diabetes in North Thailand: A Hospital-Based Observational Study. Frontiers in Endocrinology, 2022, 13, .	3.5	5
5	Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction. American Journal of Cardiovascular Drugs, 2022, 22, 577-590.	2.2	12
6	Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction. International Journal of Cardiology, 2021, 322, 183-190.	1.7	31
7	Effects of pharmacist interventions on heart failure outcomes: A systematic review and meta-analysis. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 871-882.	1.0	11
8	Cost-Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand. Diabetes Therapy, 2021, 12, 1947-1963.	2.5	5
9	Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand. Clinical Drug Investigation, 2021, 41, 907-915.	2.2	13
10	Cost-effectiveness analysis of pharmacist interventions in patients with heart failure in Thailand. Journal of the American Pharmacists Association: JAPhA, 2021, , .	1.5	2
11	Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation. Heart Lung and Circulation, 2020, 29, 390-400.	0.4	20
12	Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand. Value in Health Regional Issues, 2020, 21, 9-16.	1.2	5
13	Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Heart Failure in Thailand. ClinicoEconomics and Outcomes Research, 2020, Volume 12, 579-588.	1.9	1
14	Treatment Costs for Patients with Chronic Kidney Disease Who Received Multidisciplinary Care in a District Hospital in Thailand. ClinicoEconomics and Outcomes Research, 2020, Volume 12, 223-231.	1.9	6
15	An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand. Vaccine, 2019, 37, 4551-4560.	3.8	20
16	Cost-benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand. ClinicoEconomics and Outcomes Research, 2019, Volume 11, 423-430.	1.9	2
17	Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction. ClinicoEconomics and Outcomes Research, 2019, Volume 11, 767-777.	1.9	5
18	Relationship of medication adherence and quality of life among heart failure patients. Heart and Lung: Journal of Acute and Critical Care, 2019, 48, 105-110.	1.6	42

#	ARTICLE	IF	CITATIONS
19	Biphasic insulin aspart 30 treatment for people with type 2 diabetes: a budget impact analysis based in Thailand. <i>Current Medical Research and Opinion</i> , 2018, 34, 369-375.	1.9	1
20	Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials. <i>International Journal of Hepatology</i> , 2018, 2018, 1-13.	1.1	79
21	Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 405-413.	2.2	24
22	Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 113-125.	4.4	51
23	Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand. <i>Current Medical Research and Opinion</i> , 2017, 33, 955-961.	1.9	5
24	Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer's perspective. <i>Journal of Medical Economics</i> , 2017, 20, 991-999.	2.1	9
25	Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand. <i>Journal of Medical Economics</i> , 2017, 20, 171-181.	2.1	11
26	Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 281-292.	2.1	10
27	Cost-Effectiveness Analysis of Fondaparinux vs Enoxaparin in Non-ST Elevation Acute Coronary Syndrome in Thailand. <i>Heart Lung and Circulation</i> , 2015, 24, 860-868.	0.4	5
28	Validation of the Thai QOL-AD version in Alzheimer's patients and caregivers. <i>Australasian Medical Journal</i> , 2014, 7, 251-259.	0.1	10
29	Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand. <i>Thrombosis Research</i> , 2014, 134, 1278-1284.	1.7	14
30	Epidermal Growth Factor Receptor Mutation Testing in Thailand: A Cost-Utility Analysis. <i>Value in Health Regional Issues</i> , 2014, 3, 39-43.	1.2	5
31	Handling time in economic evaluation studies. <i>Journal of the Medical Association of Thailand = Chotmaihet Thangphaet</i> , 2014, 97 Suppl 5, S50-8.	0.1	16
32	Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand. <i>Thrombosis Research</i> , 2013, 132, 437-443.	1.7	23
33	Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012, 8, 53-61.	1.1	13
34	Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand. <i>International Journal of Clinical Pharmacy</i> , 2012, 34, 105-112.	2.1	43
35	Transcatheter aortic valve implantation in patients with severe symptomatic aortic valve stenosis: systematic review of cost-effectiveness analysis. <i>European Journal of Health Economics</i> , 0, , .	2.8	2